Patient
SITE013-0226
enrolled Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE013 (USA) (Dr. Clarke)
consented 2026-06-01
Adverse events
4
Serious AEs
1
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 4
Grade 1 Decreased appetite — outcome: UNKNOWN; onset 2023-02-22 (study day 84); relationship: not assessed
Grade 4 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-01-17 (study day 48); relationship: not assessed; serious criteria: life-threatening
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-12-28 (study day 28); relationship: NOT RELATED
Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-12-03 (study day 3); relationship: not assessed
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.